Abiopharma

News list

Chen Anqiang 🟡 adjusted position in 4.3K shares (1 derivative) of Tuniu Corp (TOUR) at $0.00 Transaction Date: Sep 01, 2026 | Filing ID: 104884

Full text

News bot Sept. 3, 2026, 10:16 a.m.
🔍 Chen Anqiang (Executive)

Company: Tuniu Corp (TOUR)

Report Date: 2026-09-01
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 149
- Total shares sold: 4,470
Detailed Transactions and Holdings:
- Acquired 149 shares of American depositary share at $0.003 per share (Direct)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,969.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
- Sold 4,470 shares of Option (Right to Buy) at $0.0001 per share (Derivative)
  Date: 2026-09-01 | Code: M | Expires: 2026-09-05 | Exercise: 2019-03-05 | equity_swap_involved: 0 | shares_owned_after: 27.00 | transaction_form_type: 4
Footnotes:
- F1: Effective April 22, 2026, the Issuer changed the ratio of its American Depositary Shares ("ADSs") from one (1) ADS representing three (3) Class A ordinary shares to one (1) ADS representing thirty (30) Class A ordinary shares (the "ADS Ratio Change"). The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
- F2: The ADSs were acquired upon cash exercise of the options covering 4,470 Class A ordinary shares at an exercise price of $0.0001 per Class A ordinary share. The exercise resulted in the acquisition of 149 ADSs.